Neoadjuvant chemotherapy for primary cutaneous/soft tissue angiosarcoma: Determining tumor behavior prior to surgical resection

Journal of Surgical Oncology

Volumn 111, Issue 7, 2015, Pages 829-833

  Oxenberg, Jacqueline ^a   Khushalani, Nikhil I ^a   Salerno, Kilian E ^a   Attwood, Kristopher ^a   Kane, John M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

angiosarcoma; cutaneous; neoadjuvant chemotherapy

Indexed keywords

DOCETAXEL; GEMCITABINE; PACLITAXEL; ANTINEOPLASTIC AGENT;

ABDOMINAL INFECTION; ADOLESCENT; ADULT; AGED; ANGIOSARCOMA; ARTICLE; BLEEDING; CANCER ADJUVANT THERAPY; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SOFT TISSUE SARCOMA; TREATMENT RESPONSE; WOUND CLOSURE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CANCER GRADING; HEMANGIOSARCOMA; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SKIN NEOPLASMS; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HEMANGIOSARCOMA; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 84928796139     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23891     Document Type: Article

References (28)

1. Albores-Saavedra J, Schwartz AM, Henson DE, et al.: Cutaneous angiosarcoma. analysis of 434 cases from the surveillance, epidemiology, and end results program 1973-2007. Ann Diagn Pathol 2011; 15: 93-97.
2. Mery CM, George S, Bertagnolli MM, et al.: Secondary sarcomas after radiotherapy for breast cancer: Sustained risk and poor survival. Cancer. 2009; 115: 4055-4063.
3. Fury MG, Antonescu CR, Van Zee KJ, et al.: A 14-year retrospective review of angiosarcoma: Clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 2005; 11: 241-247.
4. Abraham JA, Hornicek FJ, Kaufman AM, et al.: Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol 2007; 14: 1953-1967.
5. DeMartelaere SL, Roberts D, Burgess MA, et al.: Neoadjuvant chemotherapy-specific and overall treatment outcomes in patients with cutaneous angiosarcoma of the face with periorbital involvement. Head Neck 2008; 30: 639-646.
6. Karpeh MS Jr, Caldwell C, Gaynor JJ, et al.: Vascular soft-tissue sarcomas. An analysis of tumor-related mortality. Arch Surg 1991; 126: 1474-1481.
7. Espat NJ, Lewis JJ, Woodruff JM, et al.: Confirmed angiosarcoma: Prognostic factors and outcome in 50 prospectively followed patients. Sarcoma 2000; 4: 173-177.
8. Sher T, Hennessy BT, Valero V, et al.: Primary angiosarcomas of the breast. Cancer 2007; 110: 173-178.
9. Lahat G, Dhuka AR, Lahat S, et al.: Outcome of locally recurrent and metastatic angiosarcoma. Ann Surg Oncol 2009; 16: 2502-2509.
10. Italiano A, Cioffi A, Penel N, et al.: Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer 2012; 118: 3330-3336.
11. Fata F, O'Reilly E, Ilson D, et al.: Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999; 86: 2034-2037.
12. Fujisawa Y, Nakamura Y, Kawachi Y, et al.: Comparison between taxane-based chemotherapy with conventional surgery-based therapy for cutaneous angiosarcoma: A single-center experience. J Dermatolog Treat 2014; 25: 419-423.
13. Pezzi CM, Pollock RE, Evans HL, et al.: Preoperative chemotherapy for soft-tissue sarcomas of the extremities. Ann Surg 1990; 211: 476-481.
14. Rhomberg W, Wink A, Pokrajac B, et al.: Treatment of vascular soft tissue sarcomas with razoxane, vindesine, and radiation. Int J Radiat Oncol Biol Phys 2009; 74: 187-191.
15. Schlemmer M, Reichardt P, Verweij J, et al.: Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 2008; 44: 2433-2436.
16. Skubitz KM, Haddad PA,: Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 2005; 104: 361-366.
17. Stacchiotti S, Palassini E, Sanfilippo R, et al.: Gemcitabine in advanced angiosarcoma: A retrospective case series analysis from the italian rare cancer network. Ann Oncol 2012; 23: 501-508.
18. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al.: Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a european organization for research and treatment of cancer soft tissue and bone sarcoma group study. J Clin Oncol 1999; 17: 150-157.
19. Torres K, Ravi V, Kin K, et al.: Radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer. Ann Surg Oncol 2013; 20: 1267-1274.
20. Clavien PA, Barkun J, de Oliveira ML, et al.: The clavien-dindo classification of surgical complications: Five-year experience. Ann Surg 2009; 250: 187-196.
21. Fayette J, Martin E, Piperno-Neumann S, et al.: Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: A retrospective study of 161 cases. Ann Oncol 2007; 18: 2030-2036.
22. Fata F, O'Reilly E, Ilson D, et al.: Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999; 86: 2034-2037.
23. Maki RG, D'Adamo DR, Keohan ML, et al.: Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009; 27: 3133-3140.
24. Agulnik M, Yarber JL, Okuno SH, et al.: An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol 2013; 24: 257-263.
25. Ray-Coquard I, Italiano A, Bompas E, et al.: Sorafenib for patients with advanced angiosarcoma: A phase II trial from the french sarcoma group (GSF/GETO). Oncologist 2012; 17: 260-266.
26. Kraybill WG, Harris J, Spiro IJ, et al.: Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation therapy oncology group trial 9514. J Clin Oncol 2006; 24: 619-625.
27. Penel N, Bui BN, Bay JO, et al.: Phase II trial of weekly paclitaxel for unresectable angiosarcoma: The ANGIOTAX study. J Clin Oncol. 2008; 26: 5269-5274.
28. Please check Synopsis for Table of Contents.